Ultrasound Treatment to Replenish Cells Essential for Brain Function

Our goal is to develop treatments for patients with Alzheimer’s disease by using ultrasound energy to promote the regeneration of cells producing the brain’s white matter.

Alzheimer’s disease affects both white and grey matter. The predominant cells in white matter, oligodendrocytes, produce myelin, which insulates cells to improve communication. White matter deficits can result in cell loss and communication breakdown. In a preclinical model of Alzheimer’s disease, we have discovered that non-invasive ultrasound waves can generate new oligodendrocytes that may boost myelin production. With funding, we aim to develop this innovative therapy, which has the potential to improve brain function affected by Alzheimer’s disease, including learning and memory.

In patients with Alzheimer’s disease, the white matter of the brain composed of myelin undergoes early loss. A remaining unmet need is to provide therapies to replenish and support myelin-producing cells. Our team discovered that ultrasound promotes oligodendrogenesis in a mouse model of Alzheimer’s disease. This breakthrough propelled investigations on the regenerative potential of non-invasive ultrasound treatments. Building on our pioneering work, we aim to establish the effects of ultrasound on myelin and its producing cells, and develop new treatment options for patients with Alzheimer’s.

Ultrasound technologies are advancing rapidly towards clinical trials for brain disorders. Our project could lead to groundbreaking discoveries using ultrasound waves to support and repair the white matter of the brain. The development of such treatment could help treat people with Alzheimer’s disease and other white matter disorders. Ultrasound therapy does not require brain surgery, which can benefit both patients and their caregivers. Additionally, clinicians can tailor ultrasound therapy to each patient, and use it alone or in conjunction with medication to improve their quality of life.